The Role of the Optometrist in the Evolving Management of Diabetic Retinopathy

By: Steven Ferrucci, OD, FAAO; Mrinali Gupta, MD; Allen C. Ho, MD, FACS; Rebecca Miller, OD; and Charles C. Wykoff, MD, PHD, FACS

Begin Course

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

CONTENT SOURCE This continuing education activity captures content from a round table discussion. ACTIVITY DESCRIPTION The content featured in this supplement highlights the crucial role that optometrists play in educating patients with diabetes about the potential ocular complications of their systemic disorder, the additional care that must be addressed when undergoing ocular surgery (ie, cataract), and the benefits of diabetic eye exams and early treatment. TARGET AUDIENCE This certified continuing education (CE) activity is designed for optometrists involved in the management of retinal diseases.

Expiration Date: Wednesday, August 16, 2023

Release Date: August 24, 2020

This activity is supported by a grant from Genentech, a member of the Roche Group.

Learning Objectives

Upon completion of this activity, the participant should be able to:

Describe the increasing prevalence of diabetes and diabetic retinopathy
Identify and implement screening guidelines for patients based on their risk factors
Explain to patients the need for early referral to a retina specialist
Understand advances in imaging and how these allow for ear-lier diagnosis of disease or disease progression
Identify the novel therapies under investigation for the treatment of diabetic retinopathy and diabetic macular edema

Accreditation and Designation Statement

Provided by Evolve Medical Education LLC

Evolve Medical Education LLC (Evolve) is an approved COPE administrator. COPE Approved for 1 credit hour.

Course Number: 69217-PS
Activity Number: 120057

Participation Method

TO OBTAIN CREDIT

To obtain credit for this activity, you must read the activity in its entirety and complete the Pretest/Posttest/Activity Evaluation/Satisfaction Measures Form, which consists of a series of multiple-choice questions.

Faculty and Disclosures

CHARLES C. WYKOFF, MD, PHD, FACS
Moderator
Director of Research
Retina Consultants of Houston
Houston, TX

STEVEN FERRUCCI, OD, FAAO
Chief of Optometry
Sepulveda VA Ambulatory Care Center and Nursing Home
Los Angeles, CA

MRINALI GUPTA, MD
Retina Associates of Orange County
Laguna Hills, CA

ALLEN C. HO, MD, FACS
Director of Retina Research
Wills Eye Hospital
Mid-Atlantic Retina
Philadelphia, PA

REBECCA MILLER, OD
Optometrist
Slade & Baker Vision
Houston, TX

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educa-tional activity. The following faculty/staff members have the following financial relationships with commercial interests:

Steven G. Ferrucci, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Centervue, MacuLogix; Speakers Bureau: Alcon, Genentech, Optovue, and Regeneron Pharmaceuticals.

Mrinali Gupta, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, and Carl Zeiss Meditec. Intellectual property: Sonder Research X.

Allen C. Ho, MD, FACS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the fol-lowing commercial interests in the form of Consultant: Aerpio, AGTC, Asclepix, Alcon, Allergan, Beaver VisiVisitec International, Chengdu Kanghong Biotechnology, Genentech, Gyroscope, Iconic, Iveric/Ophthotech, Iridex, Johnson & Johnson Vision, Lineage/Bio Time, ONL, Optovue, RegenxBio, Regeneron, Second Sight Medical Products, and Tyrogenix. Grant/Research Support: Aerpio, AGTC, Alcon, Allergan, Apellis, Chengdu Kanghong Biotechnology, Genentech, Gyroscope, Iconic, Iveric/Ophthotech, Johnson & Johnson Vision, Lineage/BioTime, National Institutes of Health, Optovue, ProQR, RegenxBio, Second Sight Medical Products , and Regeneron. Other Financial/Material Support: Covalent Medical and ONL.

Rebecca Miller, OD, and/or spouse/partner has no financial relationships with commercial interests.

Charles C. Wykoff, MD, PhD, FACS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allergan, Genentech, Novartis, and Regeneron. Grant/Research Support: Allergan, Genentech, Novartis, and Regeneron. Speaker’s Bureau: Regeneron.

EDITORIAL SUPPORT DISCLOSURES

The Evolve staff and planners have no financial relationships with commercial interests. Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Modern Optometry, or Genentech.